

Regular Meeting of the

Santa Clara County Health Authority Pharmacy and Therapeutics Committee

Thursday, December 19, 2019, 6:00 PM - 8:00 PM

Santa Clara Family Health Plan, Redwood Conference Room
6201 San Ignacio Ave, San Jose, CA 95119

MINUTES (OPEN)

Members Present

Ali Alkoraishi, MD
Dang Huynh, PharmD, Director of Pharmacy
Jesse Parashar-Rokicki, MD
Jimmy Lin, MD, Chair
Laurie Nakahira, DO, Chief Medical Officer
Peter Nguyen, DO
Xuan Cung, PharmD

Members Absent

Amara Balakrishnan, MD
Dolly Goel, MD
Hao Bui, BS, RPh
Minh Thai, MD
Narinder Singh, PharmD

Staff Present

Duyen Nguyen, PharmD
Nancy Aguirre, Administrative Assistant
Tami Otomo, PharmD

Others Present

Alan Kaska, Abbott Labs, Public
Amy McCarty, PharmD, MedImpact

1. Roll Call

Jimmy Lin, MD, Chair, called the meeting to order at 6:06pm. Roll call was taken and a quorum was not established.

2. Public Comment

Alan Kaska, Abbott Labs, talked about continuous glucose monitoring (CGM) devices for diabetes care. Abbott's CGM product, FreeStyle Libre, involves reading a person's blood glucose level with a reader and sensor instead of using the traditional fingerstick method. Mr. Kaska shared that Abbott Labs introduced the FreeStyle Libre CGM products at a lower cost than competitors.

3. Open Meeting Minutes

The review of the 3Q2019 Pharmacy and Therapeutics Committee open meeting minutes was deferred until a quorum was established.

4. Standing Agenda Items

a. Chief Medical Officer Health Plan Updates

Laurie Nakahira, DO, Chief Medical Officer, Santa Clara Family Health Plan (SCFHP), reviewed the following Health Plan updates:

- I. The Healthy Kids line of business has ended. The children who were enrolled in Healthy Kids were transitioned into the Medi-Cal line of business, which offers more benefits. All but two of the 3,500 children were transitioned into Medi-Cal on October 1, 2019. The two children (siblings) who did not meet criteria for Medi-Cal are being transitioned into Valley Kids. This transition should take full effect on January 1, 2020. Until that date, the two siblings will be covered by SCFHP.
- II. One of SCFHP's durable medical equipment (DME) providers, California Home Medical Equipment (CHME), contract is terminating. Their contract ends on December 31, 2019.
- III. SCFHP completed the Centers for Medicare and Medicaid Services (CMS) audit with a total of five findings. There will be one more audit to complete.
- IV. Dr. Nakahira announced that SCFHP signed a lease for a new Community Resource Center (CRC) located in San Jose, near McKee Road and North Capitol Avenue. Member engagement, educational classes, and physical activity classes are a few of the resources that will be available to members within the CRC.
- V. SCFHP has a new website and launched a new mobile app. The mobile app is user friendly and feedback on this new resource is highly encouraged.
- VI. Presently, developmental screenings are being conducted during well child visits. However, providers have not been billing for them. Proposition 56 offers an extra payment to providers for performing this task. SCFHP will be working with some of the clinics to ensure providers obtain credit for completed developmental screenings.

b. Plan/Global Medi-Cal Drug Use Review

Tami Otomo, PharmD, SCFHP, provided the final update on the Retrospective Drug Utilization Review (DUR) Morphine Equivalency Initiative program, which aimed to improve the quality of pain treatment and prevent opioid overdose in members with at least one month of prescription opioid claims exceeding 120 morphine equivalent daily dose (MEDD).

Dr. Otomo noted that opioid safety edits at point-of-sale (POS) were implemented on October 1, 2019 for all Medi-Cal members.

Ali Alkoraishi, MD, Committee Member, asked where SCFHP acquired their data. Dr. Otomo explained that the data was obtained from approved pharmacy claims for opioid prescriptions.

Peter Nguyen, DO, Committee Member, arrived at 6:18pm. A quorum was established at this time.

c. Appeals & Grievance 3Q2019 Report

Dang Huynh, PharmD, Director of Pharmacy, SCFHP, presented the 3Q2019 Grievance & Appeals Report.

Dr. Nguyen asked about the number of prior authorization requests with subsequent appeals. Dr. Huynh explained that there is a 24-hour turnaround time for Medi-Cal. If the initial request does not have the necessary information, SCFHP will conduct telephonic outreach to the requesting provider to gather

supporting information. If the provider's office does not submit the supporting information within the turnaround time, then a denial will be made due to not having enough information to approve the request.

For Cal MediConnect (CMC), the majority of appeals are requests for high risk medications (HRM). HRM authorization requests require providers to submit an attestation acknowledging that the medication they are prescribing is considered high risk, but the benefits outweigh the risks for their patient. Dr. Lin asked if this is a state requirement. Dr. Huynh replied that CMS encourages the monitoring of HRM drugs. Dr. Huynh will request that Appeals & Grievances provide details about the other types of appeals for the next P&T Committee meeting.

d. National Committee for Quality Assurance (NCQA) Member Connection Standards – 2019 Pharmacy Report

Duyen Nguyen, PharmD, SCFHP, reported that there were no issues found in the required annual NCQA self-audit of SCFHP's member portal, resulting in a score of 100% in all measurements of quality and accuracy.

e. CY2020 Utilization Management Drug PA Grid

Dr. Otomo presented the Utilization Management Drug Prior Authorization (PA) grid for CY2020 and noted that it was approved at the most recent 4Q2019 Utilization Management Committee meeting.

SCFHP added newly released and soon-to-be released biosimilars to the PA grid. Dr. Otomo noted that if a biosimilar is available, SCFHP requires a step therapy for the brand name product.

At 6:30pm, Dr. Lin resumed the Committee's review of the 3Q2019 Pharmacy and Therapeutics Committee open meeting minutes, as a quorum was established upon Dr. Nguyen's arrival.

Dr. Nguyen motioned to accept the open meeting minutes as presented, and it was seconded by Dr. Alkoraishi. Motion carried.

Adjourn to Closed Session

Pursuant to Welfare and Institutions Code Section 14078.36 (w)

5. Closed Meeting Minutes

The 3Q2019 Pharmacy and Therapeutics Committee closed meeting minutes were reviewed as presented.

Dr. Nguyen motioned to accept the closed meeting minutes as presented, and it was seconded by Dr. Alkoraishi. Motion carried.

6. Metrics and Financial Updates

a. Membership Report

Dr. Nakahira presented the membership report.

b. Pharmacy Dashboard

Dr. Otomo presented the pharmacy dashboard.

c. Drug Use Evaluation

Dr. Huynh presented a follow-up to the 1Q19 Drug Use Evaluation (DUE) program.

d. Drug Utilization & Spend

Dr. McCarty presented the Drug Utilization & Spend.

7. Discussion and Recommendations for Changes to SCFHP's CMC Formulary & Coverage Determination Criteria

a. Pharmacy Benefit Manager 3Q2019 P&T Minutes

b. Pharmacy Benefit Manager 4Q2019 P&T Part D Actions

Dr. McCarty presented the PBM's Medicare Part D Pharmacy & Therapeutics minutes and actions.

Dr. Nguyen motioned to accept the PBM's 3Q2019 P&T Minutes and 4Q2019 P&T Part D Actions, and it was seconded by Dr. Nakahira. Motion carried.

8. Discussion and Recommendations for Changes to SCFHP's Medi-Cal & Prior Authorization Criteria

a. Old Business/Follow-Up

i. Continuous Glucose Monitors (CGM)

Dr. Huynh reviewed the cost of Abbott FreeStyle Libre's CGM sensor.

ii. Opioid Point-of-Sale Safety Edits

Dr. Huynh reviewed the provider memo faxed out on October 1, 2019 with details about these opioid safety edits.

iii. Insulin Vial and Insulin Pen

Dr. Huynh reviewed the cost difference between an insulin pen and an insulin vial.

iv. Prior Authorization Approval Length

Dr. Huynh addressed Dr. Nguyen's question from the previous P&T Committee meeting regarding the consideration of approving PAs.

b. Formulary Modifications

Dr. Otomo presented Medi-Cal formulary changes.

Dr. Nguyen motioned to accept the Formulary Modifications, and it was seconded by Jesse Parashar-Rokicki, MD, Committee Member. Motion carried.

c. Fee-for-Service Contract Drug List Comparability

Dr. McCarty reviewed the summary of changes to the Medi-Cal Fee-for-Service (FFS) Contract Drug List (CDL).

Dr. Nguyen motioned to accept the recommendation that no action was needed by SCFHP, and it was seconded by Dr. Parashar-Rokicki. Motion carried.

d. Prior Authorization Criteria

Dr. Duyen Nguyen presented the following PA criteria:

i. New or Revised Criteria:

1. Non-Formulary
2. Hepatitis C Policy
3. Epclusa
4. Mavyret
5. Norditropin Flexpro
6. Retacrit

ii. Annual Review:

1. Zarxio

Dr. Nguyen motioned to accept the PA criteria as presented, and it was seconded by Dr. Alkoraishi. Motion carried.

9. New Drug and Class Reviews

Dr. McCarty presented the following new drugs and class reviews:

a. Review

- i. **Vumerity (diroximel fumarate)**
- ii. **Nourianz (istradefylline)**
- iii. **Glucagon-like peptide-1 (GLP-1) Class – Diabetes**

Dr. Nguyen motioned to accept the New Drugs and Class Reviews as presented, and it was seconded by Dr. Cung. Motion carried.

b. Informational Only

- i. Adakveo (crizanlizumab) – Sickle Cell Disease
- ii. Beovu (brolucizumab) – Age-Related Macular Degeneration
- iii. Nubeqa (darolutamide) – Prostate Cancer
- iv. Rozlytrek (entrectinib) – Oncology
- v. Inrebic (fedratinib) – Oncology
- vi. Reyvow (lasmiditan) – Migraine
- vii. Ubrogepant – Migraine
- viii. Rimegepant – Migraine
- ix. Palforzia (AR101) – Peanut Allergy
- x. Bonsity (teriparatide) – Osteoporosis
- xi. Pretomainid – Tuberculosis
- xii. Aklied (triparatide) – Acne
- xiii. Guideline Updates – Pulmonary Arterial Hypertension
- xiv. Biosimilar Update
- xv. New and Expanded Indications

No questions were asked about the Informational Only items.

Reconvene in Open Session

10. Discussion Items

a. New and Generic Pipeline

Dr. McCarty noted an upcoming high impact-interest agent coming in 1Q2020 for peanut allergies. A second agent for peanut allergies will be released in the second half of 2020.

Dr. McCarty shared that generic Novolog Flexpen and Novolog vial will be available early 2020. These drugs are not on SCFHP's Medi-Cal formulary.

11. Adjournment

The next Pharmacy and Therapeutics Committee meeting will be on March 19, 2020. The meeting was adjourned at 7:37pm.

Signed via Teleconference

04/30/2020

Jimmy Lin, MD, Chair of Pharmacy & Therapeutics Committee

Date